The German federation of industrial health funds, the BKK, has urgeddoctors to reduce prescribing and to be more economical. In recent months, it says, Health Minister Horst Seehofer has drastically raised patient charges, yet at the same time the means of controlling soaring drug costs have been softened.
The patient's share of charges in total drug spending will have risen from 9% in 1996 to 20% in 1998, it says. Thus, additional charges on drugs have risen overall from 3 billion marks in 1996 ($1.64 billion) to over 5.5 billion marks in 1997 and will reach 7 billion marks in 1998.
The reason for the increase is the patient charge rise of 1 mark per pack on January 1 this year and a further 5 marks in July last, says the BKK, adding that the use of fixed price level support agreements is now unavoidable. These were originally introduced back in 1989, and the BKK believes they would effectively stabilize prices and save some 3 billion marks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze